{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,14]],"date-time":"2025-11-14T17:20:18Z","timestamp":1763140818931},"reference-count":57,"publisher":"Public Library of Science (PLoS)","issue":"12","license":[{"start":{"date-parts":[[2015,12,1]],"date-time":"2015-12-01T00:00:00Z","timestamp":1448928000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0143897","type":"journal-article","created":{"date-parts":[[2015,12,1]],"date-time":"2015-12-01T20:23:44Z","timestamp":1449001424000},"page":"e0143897","update-policy":"http:\/\/dx.doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":14,"title":["The Bone Marrow-Mediated Protection of Myeloproliferative Neoplastic Cells to Vorinostat and Ruxolitinib Relies on the Activation of JNK and PI3K Signalling Pathways"],"prefix":"10.1371","volume":"10","author":[{"given":"Bruno A.","family":"Cardoso","sequence":"first","affiliation":[]},{"given":"H\u00e9lio","family":"Belo","sequence":"additional","affiliation":[]},{"given":"Jo\u00e3o T.","family":"Barata","sequence":"additional","affiliation":[]},{"given":"Ant\u00f3nio M.","family":"Almeida","sequence":"additional","affiliation":[]}],"member":"340","published-online":{"date-parts":[[2015,12,1]]},"reference":[{"issue":"17","key":"ref1","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1056\/NEJM197610212951702","article-title":"Polycythemia vera: stem-cell and probable clonal origin of the disease","volume":"295","author":"JW Adamson","year":"1976","journal-title":"N Engl J Med"},{"issue":"5","key":"ref2","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1182\/blood.V58.5.916.916","article-title":"Evidence that essential thrombocythemia is a clonal disorder with origin in a multipotent stem cell","volume":"58","author":"PJ Fialkow","year":"1981","journal-title":"Blood"},{"issue":"3","key":"ref3","doi-asserted-by":"crossref","first-page":"171","DOI":"10.3322\/caac.20009","article-title":"Advances in understanding and management of myeloproliferative neoplasms","volume":"59","author":"AM Vannucchi","year":"2009","journal-title":"CA Cancer J Clin"},{"issue":"4","key":"ref4","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/j.ccr.2005.03.023","article-title":"Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis","volume":"7","author":"RL Levine","year":"2005","journal-title":"Cancer Cell"},{"issue":"17","key":"ref5","doi-asserted-by":"crossref","first-page":"1779","DOI":"10.1056\/NEJMoa051113","article-title":"A gain-of-function mutation of JAK2 in myeloproliferative disorders","volume":"352","author":"R Kralovics","year":"2005","journal-title":"N Engl J Med"},{"issue":"7037","key":"ref6","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.1038\/nature03546","article-title":"A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera","volume":"434","author":"C James","year":"2005","journal-title":"Nature"},{"issue":"9464","key":"ref7","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1016\/S0140-6736(05)74230-6","article-title":"Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders","volume":"365","author":"EJ Baxter","year":"2005","journal-title":"Lancet"},{"issue":"7","key":"ref8","doi-asserted-by":"crossref","first-page":"1723","DOI":"10.1182\/blood-2011-02-292102","article-title":"New mutations and pathogenesis of myeloproliferative neoplasms","volume":"118","author":"W Vainchenker","year":"2011","journal-title":"Blood"},{"issue":"25","key":"ref9","doi-asserted-by":"crossref","first-page":"2391","DOI":"10.1056\/NEJMoa1312542","article-title":"Somatic CALR mutations in myeloproliferative neoplasms with nonmutated JAK2","volume":"369","author":"J Nangalia","year":"2013","journal-title":"N Engl J Med"},{"issue":"25","key":"ref10","doi-asserted-by":"crossref","first-page":"2379","DOI":"10.1056\/NEJMoa1311347","article-title":"Somatic mutations of calreticulin in myeloproliferative neoplasms","volume":"369","author":"T Klampfl","year":"2013","journal-title":"N Engl J Med"},{"issue":"9","key":"ref11","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1056\/NEJMoa1110557","article-title":"A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis","volume":"366","author":"S Verstovsek","year":"2012","journal-title":"N Engl J Med"},{"issue":"9","key":"ref12","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1056\/NEJMoa1110556","article-title":"JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis","volume":"366","author":"C Harrison","year":"2012","journal-title":"N Engl J Med"},{"issue":"3","key":"ref13","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1111\/bjh.12384","article-title":"Phase II trial of panobinostat, an oral pan-deacetylase inhibitor in patients with primary myelofibrosis, post-essential thrombocythaemia, and post-polycythaemia vera myelofibrosis","volume":"162","author":"DJ Deangelo","year":"2013","journal-title":"Br J Haematol"},{"issue":"4","key":"ref14","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1111\/bjh.12416","article-title":"A phase II study of vorinostat (MK-0683) in patients with polycythaemia vera and essential thrombocythaemia","volume":"162","author":"CL Andersen","year":"2013","journal-title":"Br J Haematol"},{"issue":"4","key":"ref15","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1111\/j.1365-2141.2010.08266.x","article-title":"A pilot study of the Histone-Deacetylase inhibitor Givinostat in patients with JAK2V617F positive chronic myeloproliferative neoplasms","volume":"150","author":"A Rambaldi","year":"2010","journal-title":"Br J Haematol"},{"issue":"11","key":"ref16","doi-asserted-by":"crossref","first-page":"3008","DOI":"10.1158\/1078-0432.CCR-11-3145","article-title":"Ruxolitinib: the first FDA approved therapy for the treatment of myelofibrosis","volume":"18","author":"J Mascarenhas","year":"2012","journal-title":"Clin Cancer Res"},{"issue":"4","key":"ref17","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1002\/cncr.28441","article-title":"A phase 2 study of ruxolitinib, an oral JAK1 and JAK2 inhibitor, in patients with advanced polycythemia vera who are refractory or intolerant to hydroxyurea","volume":"120","author":"S Verstovsek","year":"2014","journal-title":"Cancer"},{"issue":"16","key":"ref18","doi-asserted-by":"crossref","first-page":"3779","DOI":"10.1182\/blood-2011-02-336743","article-title":"Efficacy of vorinostat in a murine model of polycythemia vera","volume":"119","author":"H Akada","year":"2012","journal-title":"Blood"},{"issue":"6","key":"ref19","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1002\/stem.1370","article-title":"Concise Review: Current Concepts in Bone Marrow Microenvironmental Regulation of Hematopoietic Stem and Progenitor Cells","volume":"31","author":"JN Smith","year":"2013","journal-title":"Stem Cells"},{"issue":"8","key":"ref20","doi-asserted-by":"crossref","first-page":"3026","DOI":"10.1182\/blood-2008-06-158386","article-title":"Does primary myelofibrosis involve a defective stem cell niche? From concept to evidence","volume":"112","author":"JJ Lataillade","year":"2008","journal-title":"Blood"},{"issue":"5909","key":"ref21","doi-asserted-by":"crossref","first-page":"1861","DOI":"10.1126\/science.1164390","article-title":"Leukemic cells create bone marrow niches that disrupt the behavior of normal hematopoietic progenitor cells","volume":"322","author":"A Colmone","year":"2008","journal-title":"Science"},{"issue":"9","key":"ref22","doi-asserted-by":"crossref","first-page":"2519","DOI":"10.1158\/1078-0432.CCR-07-2223","article-title":"The bone marrow microenvironment as a tumor sanctuary and contributor to drug resistance","volume":"14","author":"MB Meads","year":"2008","journal-title":"Clin Cancer Res"},{"issue":"3","key":"ref23","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1016\/j.leukres.2011.08.001","article-title":"Interactions between acute lymphoblastic leukemia and bone marrow stromal cells influence response to therapy","volume":"36","author":"Y Tesfai","year":"2012","journal-title":"Leuk Res"},{"issue":"5","key":"ref24","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1158\/1535-7163.MCT-07-2331","article-title":"Stromal-mediated protection of tyrosine kinase inhibitor-treated BCR-ABL-expressing leukemia cells","volume":"7","author":"E Weisberg","year":"2008","journal-title":"Mol Cancer Ther"},{"issue":"10","key":"ref25","doi-asserted-by":"crossref","first-page":"2233","DOI":"10.1038\/leu.2012.96","article-title":"Using combination therapy to override stromal-mediated chemoresistance in mutant FLT3-positive AML: synergism between FLT3 inhibitors, dasatinib\/multi-targeted inhibitors and JAK inhibitors","volume":"26","author":"E Weisberg","year":"2012","journal-title":"Leukemia"},{"issue":"10","key":"ref26","doi-asserted-by":"crossref","first-page":"1824","DOI":"10.1182\/blood-2012-02-412890","article-title":"Microenvironmental protection of CML stem and progenitor cells from tyrosine kinase inhibitors through N-cadherin and Wnt-beta-catenin signaling","volume":"121","author":"B Zhang","year":"2013","journal-title":"Blood"},{"issue":"11","key":"ref27","doi-asserted-by":"crossref","first-page":"3831","DOI":"10.1158\/0008-5472.CAN-10-4002","article-title":"Bone marrow stroma-secreted cytokines protect JAK2(V617F)-mutated cells from the effects of a JAK2 inhibitor","volume":"71","author":"T Manshouri","year":"2011","journal-title":"Cancer Res"},{"issue":"3","key":"ref28","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1038\/sj.leu.2404081","article-title":"JAK2 V617F tyrosine kinase mutation in cell lines derived from myeloproliferative disorders","volume":"20","author":"H Quentmeier","year":"2006","journal-title":"Leukemia"},{"issue":"1","key":"ref29","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1038\/sj.leu.2401608","article-title":"Establishment and characterization of a new human megakaryoblastic cell line (SET-2) that spontaneously matures to megakaryocytes and produces platelet-like particles","volume":"14","author":"K Uozumi","year":"2000","journal-title":"Leukemia"},{"issue":"2","key":"ref30","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1002\/(SICI)1097-0142(20000115)88:2<344::AID-CNCR14>3.0.CO;2-6","article-title":"Derivation of a new hematopoietic cell line with endothelial features from a patient with transformed myeloproliferative syndrome: a case report","volume":"88","author":"W Fiedler","year":"2000","journal-title":"Cancer"},{"issue":"10","key":"ref31","doi-asserted-by":"crossref","first-page":"3477","DOI":"10.1073\/pnas.82.10.3477","article-title":"Generation of functional clonal cell lines from human bone marrow stroma","volume":"82","author":"K Harigaya","year":"1985","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"3","key":"ref32","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1124\/pr.58.3.10","article-title":"Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies","volume":"58","author":"TC Chou","year":"2006","journal-title":"Pharmacol Rev"},{"issue":"1","key":"ref33","doi-asserted-by":"crossref","first-page":"e53766","DOI":"10.1371\/journal.pone.0053766","article-title":"Vorinostat induces apoptosis and differentiation in myeloid malignancies: genetic and molecular mechanisms","volume":"8","author":"G Silva","year":"2013","journal-title":"PLoS One"},{"issue":"10","key":"ref34","doi-asserted-by":"crossref","first-page":"1578","DOI":"10.1038\/leu.2011.140","article-title":"TAL1\/SCL is downregulated upon histone deacetylase inhibition in T-cell acute lymphoblastic leukemia cells","volume":"25","author":"BA Cardoso","year":"2011","journal-title":"Leukemia"},{"issue":"4","key":"ref35","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1182\/blood.V85.4.997.bloodjournal854997","article-title":"Functionally distinct human marrow stromal cell lines immortalized by transduction with the human papilloma virus E6\/E7 genes","volume":"85","author":"BA Roecklein","year":"1995","journal-title":"Blood"},{"issue":"15","key":"ref36","doi-asserted-by":"crossref","first-page":"3109","DOI":"10.1182\/blood-2009-04-214957","article-title":"Preclinical characterization of the selective JAK1\/2 inhibitor INCB018424: therapeutic implications for the treatment of myeloproliferative neoplasms","volume":"115","author":"A Quintas-Cardama","year":"2010","journal-title":"Blood"},{"issue":"5","key":"ref37","doi-asserted-by":"crossref","first-page":"2927","DOI":"10.1128\/JVI.03406-13","article-title":"Histone deacetylase inhibitors potentiate vesicular stomatitis virus oncolysis in prostate cancer cells by modulating NF-kappaB-dependent autophagy","volume":"88","author":"L Shulak","year":"2014","journal-title":"J Virol"},{"issue":"4","key":"ref38","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1080\/10428190400027852","article-title":"Interleukin-7 in T-cell acute lymphoblastic leukemia: an extrinsic factor supporting leukemogenesis?","volume":"46","author":"JT Barata","year":"2005","journal-title":"Leuk Lymphoma"},{"issue":"2","key":"ref39","doi-asserted-by":"crossref","first-page":"894","DOI":"10.1096\/fj.11-193078","article-title":"Identification of oncostatin M as a JAK2 V617F-dependent amplifier of cytokine production and bone marrow remodeling in myeloproliferative neoplasms","volume":"26","author":"G Hoermann","year":"2012","journal-title":"FASEB J"},{"issue":"7","key":"ref40","doi-asserted-by":"crossref","first-page":"3751","DOI":"10.1182\/blood-2007-07-102186","article-title":"The Jak2V617F oncogene associated with myeloproliferative diseases requires a functional FERM domain for transformation and for expression of the Myc and Pim proto-oncogenes","volume":"111","author":"G Wernig","year":"2008","journal-title":"Blood"},{"issue":"5","key":"ref41","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1158\/1535-7163.MCT-12-0862","article-title":"Dual PI3K\/AKT\/mTOR inhibitor BEZ235 synergistically enhances the activity of JAK2 inhibitor against cultured and primary human myeloproliferative neoplasm cells","volume":"12","author":"W Fiskus","year":"2013","journal-title":"Mol Cancer Ther"},{"issue":"17","key":"ref42","doi-asserted-by":"crossref","first-page":"3923","DOI":"10.1200\/JCO.2005.14.167","article-title":"Phase I study of an oral histone deacetylase inhibitor, suberoylanilide hydroxamic acid, in patients with advanced cancer","volume":"23","author":"WK Kelly","year":"2005","journal-title":"J Clin Oncol"},{"issue":"12","key":"ref43","doi-asserted-by":"crossref","first-page":"1644","DOI":"10.1177\/0091270010389469","article-title":"The pharmacokinetics, pharmacodynamics, and safety of orally dosed INCB018424 phosphate in healthy volunteers","volume":"51","author":"JG Shi","year":"2011","journal-title":"J Clin Pharmacol"},{"issue":"24","key":"ref44","doi-asserted-by":"crossref","first-page":"6215","DOI":"10.1182\/blood-2008-05-158311","article-title":"Targeting the leukemia microenvironment by CXCR4 inhibition overcomes resistance to kinase inhibitors and chemotherapy in AML","volume":"113","author":"Z Zeng","year":"2009","journal-title":"Blood"},{"issue":"2","key":"ref45","doi-asserted-by":"crossref","first-page":"e56473","DOI":"10.1371\/journal.pone.0056473","article-title":"Selective Akt inhibitors synergize with tyrosine kinase inhibitors and effectively override stroma-associated cytoprotection of mutant FLT3-positive AML cells","volume":"8","author":"E Weisberg","year":"2013","journal-title":"PLoS One"},{"issue":"1","key":"ref46","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1182\/blood-2003-07-2554","article-title":"Activation of the MAP kinase pathway by c-Kit is PI-3 kinase dependent in hematopoietic progenitor\/stem cell lines","volume":"104","author":"E Wandzioch","year":"2004","journal-title":"Blood"},{"issue":"15","key":"ref47","doi-asserted-by":"crossref","first-page":"3383","DOI":"10.1182\/blood-2011-11-370130","article-title":"Regulation of dendritic cell development by GM-CSF: molecular control and implications for immune homeostasis and therapy","volume":"119","author":"L van de Laar","year":"2012","journal-title":"Blood"},{"issue":"5","key":"ref48","doi-asserted-by":"crossref","first-page":"e19829","DOI":"10.1371\/journal.pone.0019829","article-title":"An shRNA-based screen of splicing regulators identifies SFRS3 as a negative regulator of IL-1beta secretion","volume":"6","author":"P Moura-Alves","year":"2011","journal-title":"PLoS One"},{"issue":"4","key":"ref49","doi-asserted-by":"crossref","first-page":"e35646","DOI":"10.1371\/journal.pone.0035646","article-title":"MEKK1-MKK4-JNK-AP1 pathway negatively regulates Rgs4 expression in colonic smooth muscle cells","volume":"7","author":"Y Zhang","year":"2012","journal-title":"PLoS One"},{"issue":"3","key":"ref50","doi-asserted-by":"crossref","first-page":"e0118473","DOI":"10.1371\/journal.pone.0118473","article-title":"Sphingosine-1-phosphate mediates ICAM-1-dependent monocyte adhesion through p38 MAPK and p42\/p44 MAPK-dependent Akt activation","volume":"10","author":"CC Lin","year":"2015","journal-title":"PLoS One"},{"issue":"5","key":"ref51","doi-asserted-by":"crossref","first-page":"e26845","DOI":"10.4161\/tisb.26845","article-title":"JNK is a novel regulator of intercellular adhesion","volume":"1","author":"H You","year":"2013","journal-title":"Tissue Barriers"},{"issue":"5","key":"ref52","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/j.blre.2014.06.002","article-title":"The future of JAK inhibition in myelofibrosis and beyond","volume":"28","author":"JO Mascarenhas","year":"2014","journal-title":"Blood Rev"},{"key":"ref53","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1186\/s12943-015-0388-z","article-title":"Targeting phosphatidylinositol-3-kinase pathway for the treatment of Philadelphia-negative myeloproliferative neoplasms","volume":"14","author":"R Pandey","year":"2015","journal-title":"Mol Cancer"},{"issue":"11","key":"ref54","doi-asserted-by":"crossref","first-page":"3762","DOI":"10.1172\/JCI34616","article-title":"PTEN posttranslational inactivation and hyperactivation of the PI3K\/Akt pathway sustain primary T cell leukemia viability","volume":"118","author":"A Silva","year":"2008","journal-title":"J Clin Invest"},{"issue":"5","key":"ref55","doi-asserted-by":"crossref","first-page":"819","DOI":"10.3324\/haematol.2009.013797","article-title":"Role of the PI3K\/AKT and mTOR signaling pathways in acute myeloid leukemia","volume":"95","author":"S Park","year":"2010","journal-title":"Haematologica"},{"key":"ref56","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1186\/1475-2867-7-3","article-title":"Pathway interactions between MAPKs, mTOR, PKA, and the glucocorticoid receptor in lymphoid cells","volume":"7","author":"AL Miller","year":"2007","journal-title":"Cancer Cell Int"},{"key":"ref57","article-title":"Bone marrow stromal cells protect acute myeloid leukemia cells from anti-CD44 therapy partly through regulating PI3K\/Akt-p27 axis","author":"P Chen","year":"2014","journal-title":"Mol Carcinog"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pone.0143897","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,12]],"date-time":"2024-06-12T20:28:47Z","timestamp":1718224127000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0143897"}},"subtitle":[],"editor":[{"given":"Chih-Hsin","family":"Tang","sequence":"first","affiliation":[]}],"short-title":[],"issued":{"date-parts":[[2015,12,1]]},"references-count":57,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2015,12,1]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0143897","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,12,1]]}}}